Literature DB >> 17383188

First pharmacophore-based identification of androgen receptor down-regulating agents: discovery of potent anti-prostate cancer agents.

Puranik Purushottamachar1, Aakanksha Khandelwal, Pankaj Chopra, Neha Maheshwari, Lalji K Gediya, Tadas S Vasaitis, Robert D Bruno, Omoshile O Clement, Vincent C O Njar.   

Abstract

A qualitative 3D pharmacophore model (a common feature based model or Catalyst HipHop algorithm) was developed for well-known natural product androgen receptor down-regulating agents (ARDAs). The four common chemical features identified included: one hydrophobic group, one ring aromatic group, and two hydrogen bond acceptors. This model served as a template in virtual screening of the Maybridge and NCI databases that resulted in identification of six new ARDAs (EC(50) values 17.5-212 microM). Five of these molecules strongly inhibited the growth of human prostate LNCaP cells. These novel compounds may be used as leads to develop other novel anti-prostate cancer agents.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17383188      PMCID: PMC2063997          DOI: 10.1016/j.bmc.2007.03.019

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  28 in total

1.  Antitumor agents. 250. Design and synthesis of new curcumin analogues as potential anti-prostate cancer agents.

Authors:  Li Lin; Qian Shi; Alexander K Nyarko; Kenneth F Bastow; Chin-Chung Wu; Ching-Yuan Su; Charles C-Y Shih; Kuo-Hsiung Lee
Journal:  J Med Chem       Date:  2006-06-29       Impact factor: 7.446

2.  Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells.

Authors:  N Xing; Y Chen; S H Mitchell; C Y Young
Journal:  Carcinogenesis       Date:  2001-03       Impact factor: 4.944

3.  Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells.

Authors:  Yu Zhang; Jing Ni; Edward M Messing; Eugene Chang; Chin-Rang Yang; Shuyuan Yeh
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

4.  A nonsteroidal anti-inflammatory drug, flufenamic acid, inhibits the expression of the androgen receptor in LNCaP cells.

Authors:  W Zhu; A Smith; C Y Young
Journal:  Endocrinology       Date:  1999-11       Impact factor: 4.736

5.  Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824.

Authors:  Liwei Chen; Songshu Meng; Hai Wang; Purva Bali; Wenlong Bai; Benyi Li; Peter Atadja; Kapil N Bhalla; Jie Wu
Journal:  Mol Cancer Ther       Date:  2005-09       Impact factor: 6.261

6.  Activity of and initial mechanistic studies on a novel antileishmanial agent identified through in silico pharmacophore development and database searching.

Authors:  Dawn A Delfín; Apurba K Bhattacharjee; Adam J Yakovich; Karl A Werbovetz
Journal:  J Med Chem       Date:  2006-07-13       Impact factor: 7.446

7.  A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma.

Authors:  A C Ferrari; A Chachoua; H Singh; M Rosenthal; S Taneja; M Bednar; J Mandeli; F Muggia
Journal:  Cancer       Date:  2001-06-01       Impact factor: 6.860

8.  Antitumor agents 247. New 4-ethoxycarbonylethyl curcumin analogs as potential antiandrogenic agents.

Authors:  Li Lin; Qian Shi; Ching-Yuan Su; Charles C-Y Shih; Kuo-Hsiung Lee
Journal:  Bioorg Med Chem       Date:  2006-01-19       Impact factor: 3.641

9.  Characterization of chemical constituents in Scutellaria baicalensis with antiandrogenic and growth-inhibitory activities toward prostate carcinoma.

Authors:  Michael Bonham; Jeff Posakony; Ilsa Coleman; Bruce Montgomery; Julian Simon; Peter S Nelson
Journal:  Clin Cancer Res       Date:  2005-05-15       Impact factor: 12.531

10.  Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines.

Authors:  Keiichiro Nakamura; Yutaka Yasunaga; Takehiko Segawa; Daejin Ko; Judd W Moul; Shiv Srivastava; Johng S Rhim
Journal:  Int J Oncol       Date:  2002-10       Impact factor: 5.650

View more
  3 in total

1.  Combination therapy of antiandrogen and XIAP inhibitor for treating advanced prostate cancer.

Authors:  Michael Danquah; Charles B Duke; Renukadevi Patil; Duane D Miller; Ram I Mahato
Journal:  Pharm Res       Date:  2012-03-27       Impact factor: 4.200

2.  Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts.

Authors:  Lalji K Gediya; Aashvini Belosay; Aakanksha Khandelwal; Puranik Purushottamachar; Vincent C O Njar
Journal:  Bioorg Med Chem       Date:  2007-12-08       Impact factor: 3.641

3.  A new simple and high-yield synthesis of 5α-dihydrotestosterone (DHT), a potent androgen receptor agonist.

Authors:  Puranik Purushottamachar; Vincent C O Njar
Journal:  Steroids       Date:  2012-10-05       Impact factor: 2.668

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.